echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Fda approves FoundationOne CDx as an accompanying diagnostic agent for Vitrakvi (larotrectinib) to help identify NTRK fusion-positive patients.

    Fda approves FoundationOne CDx as an accompanying diagnostic agent for Vitrakvi (larotrectinib) to help identify NTRK fusion-positive patients.

    • Last Update: 2020-10-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    In the United States, Vitrakvi ® can be used to treat patients with metastasis solid tumors with NTRK gene fusion but no known gain resistance mutations.
    . Bayer recently announced that the U.S. Food and Drug Administration (FDA) has approved FoundationOne®CDx as the first accompanying diagnostic method to help identify patients who may be suitable for neurotrophic ligenics Tyrosine kinase (NTRK) fusion that may be suitable for treatment with Vitrakvi®
    One CDx is an FDA-approved Comprehensive Genomic Analysis (CGP) test for all solid tumors.
    Vitrakvi has a good clinical performance and is the only treatment specifically developed for patients with TRK fusion cancer," said Robert Lacaz, executive director of Bayer Pharmaceuticals.
    FDA's approval of FoundationOne CDx allows us to more accurately identify patients who may benefit from this treatment.
    We look forward to working globally with Foundation Medicine to expand cancer detection and determine the right treatment."
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.